$1.1B Forma buyout gives Novo advanced sickle cell asset with potential for accelerated approval

Novo’s $1.1 billion acquisition of Forma gives the pharma a late-stage hematology asset that the biotech believes is a differentiated treatment for sickle cell disease with potential for accelerated approval.

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) will pay $20 per share to acquire Forma Therapeutics Holdings Inc. (NASDAQ:FMTX), gaining PKR activator etavopivat ahead of an interim readout this year from the Phase II/III Hibiscus trial to treat sickle cell disease (SCD)...